// Definition
The deceptive practice of CBD product companies taking existing cultivars like ACDC, R4, or Harlequin, renaming them as proprietary strains, and marketing them as exclusive genetics. Companies breed these common CBD varieties and rebrand them to create artificial scarcity and justify premium pricing, undermining the open-source ethos of medical cannabis.
// From the Episode
Skunkman Sam identified multiple companies selling the same strain under three different names, all claiming high CBD. Forest Lee contrasted this corporate approach with his own philosophy of freely distributing Harlequin. The panel discussed how this practice harms patients who need affordable access to CBD genetics.
// Source
Ep. 134 Hash Church CXXXI 131 →